A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2017-09, Vol.28, p.v228-v228 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | v228 |
|---|---|
| container_issue | |
| container_start_page | v228 |
| container_title | Annals of oncology |
| container_volume | 28 |
| creator | Pauligk, C. Lorenzen, S. Goetze, T. Riera Knorrenschild, J. Hegewisch Becker, S. Seraphin, J. Thuss-Patience, P. Kopp, H-G. Dechow, T. Vogel, A. Luley, K. Pink, D. Stahl, M. Kullmann, F. Hebart, H. Siveke, J.T. Egger, M. Homann, N. Probst, S. Al-Batran, S-E. |
| description | |
| doi_str_mv | 10.1093/annonc/mdx369.054 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx369_054</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753420379448</els_id><sourcerecordid>S0923753420379448</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1854-28b46211d8eb6f9d0e218b5f4de548be1ddfdd7dc6dcb985522f168ba79d72f03</originalsourceid><addsrcrecordid>eNp9kUuP1DAQhANaJIaFH8CtjyCRHTuvScRpNMtjpJVACM6RY3eSXjl2ZDuzO_x6PGS5cmq3VVX-5EqSt5zdcNbkW2GMNXI7qce8am5YWTxPNrysmrRmBb9KNqzJ8nRX5sXL5JX394yxqsmazbOrPThhlJ3oN6oPoOzSaUw7TSZu06IDpRJNQAfzKDzC8XgEHxZ1BjwJvYhAZoBZSE1BPKKGBwojxMC_B7sE-LG_ZYwDmagKFKP8qhmED44kWAfobQwf7L-r-8XIQNaAFE6SsZOAh9HCKE4Is7ODQ-9RgegvWGFEJ-bz08PQ68U6O58dTaTI4HbWF8ZlSqU1QZC58DocaEID7yLc9_3h_evkRS-0xzdP8zr59fnTz8PX9O7bl-Nhf5dKXpdFmtVdUWWcqxq7qm8Uw4zXXdkXCsui7pAr1Su1U7JSsmvqssyynld1J3aN2mU9y68TvuZKZ7132Ldz5BTu3HLWXmps1xrbtcY21hg9H1cPRrAToWu9jN8oUZFDGVpl6T_uP4Iwr5E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Pauligk, C. ; Lorenzen, S. ; Goetze, T. ; Riera Knorrenschild, J. ; Hegewisch Becker, S. ; Seraphin, J. ; Thuss-Patience, P. ; Kopp, H-G. ; Dechow, T. ; Vogel, A. ; Luley, K. ; Pink, D. ; Stahl, M. ; Kullmann, F. ; Hebart, H. ; Siveke, J.T. ; Egger, M. ; Homann, N. ; Probst, S. ; Al-Batran, S-E.</creator><creatorcontrib>Pauligk, C. ; Lorenzen, S. ; Goetze, T. ; Riera Knorrenschild, J. ; Hegewisch Becker, S. ; Seraphin, J. ; Thuss-Patience, P. ; Kopp, H-G. ; Dechow, T. ; Vogel, A. ; Luley, K. ; Pink, D. ; Stahl, M. ; Kullmann, F. ; Hebart, H. ; Siveke, J.T. ; Egger, M. ; Homann, N. ; Probst, S. ; Al-Batran, S-E.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx369.054</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2017-09, Vol.28, p.v228-v228</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1854-28b46211d8eb6f9d0e218b5f4de548be1ddfdd7dc6dcb985522f168ba79d72f03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>Pauligk, C.</creatorcontrib><creatorcontrib>Lorenzen, S.</creatorcontrib><creatorcontrib>Goetze, T.</creatorcontrib><creatorcontrib>Riera Knorrenschild, J.</creatorcontrib><creatorcontrib>Hegewisch Becker, S.</creatorcontrib><creatorcontrib>Seraphin, J.</creatorcontrib><creatorcontrib>Thuss-Patience, P.</creatorcontrib><creatorcontrib>Kopp, H-G.</creatorcontrib><creatorcontrib>Dechow, T.</creatorcontrib><creatorcontrib>Vogel, A.</creatorcontrib><creatorcontrib>Luley, K.</creatorcontrib><creatorcontrib>Pink, D.</creatorcontrib><creatorcontrib>Stahl, M.</creatorcontrib><creatorcontrib>Kullmann, F.</creatorcontrib><creatorcontrib>Hebart, H.</creatorcontrib><creatorcontrib>Siveke, J.T.</creatorcontrib><creatorcontrib>Egger, M.</creatorcontrib><creatorcontrib>Homann, N.</creatorcontrib><creatorcontrib>Probst, S.</creatorcontrib><creatorcontrib>Al-Batran, S-E.</creatorcontrib><title>A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kUuP1DAQhANaJIaFH8CtjyCRHTuvScRpNMtjpJVACM6RY3eSXjl2ZDuzO_x6PGS5cmq3VVX-5EqSt5zdcNbkW2GMNXI7qce8am5YWTxPNrysmrRmBb9KNqzJ8nRX5sXL5JX394yxqsmazbOrPThhlJ3oN6oPoOzSaUw7TSZu06IDpRJNQAfzKDzC8XgEHxZ1BjwJvYhAZoBZSE1BPKKGBwojxMC_B7sE-LG_ZYwDmagKFKP8qhmED44kWAfobQwf7L-r-8XIQNaAFE6SsZOAh9HCKE4Is7ODQ-9RgegvWGFEJ-bz08PQ68U6O58dTaTI4HbWF8ZlSqU1QZC58DocaEID7yLc9_3h_evkRS-0xzdP8zr59fnTz8PX9O7bl-Nhf5dKXpdFmtVdUWWcqxq7qm8Uw4zXXdkXCsui7pAr1Su1U7JSsmvqssyynld1J3aN2mU9y68TvuZKZ7132Ldz5BTu3HLWXmps1xrbtcY21hg9H1cPRrAToWu9jN8oUZFDGVpl6T_uP4Iwr5E</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Pauligk, C.</creator><creator>Lorenzen, S.</creator><creator>Goetze, T.</creator><creator>Riera Knorrenschild, J.</creator><creator>Hegewisch Becker, S.</creator><creator>Seraphin, J.</creator><creator>Thuss-Patience, P.</creator><creator>Kopp, H-G.</creator><creator>Dechow, T.</creator><creator>Vogel, A.</creator><creator>Luley, K.</creator><creator>Pink, D.</creator><creator>Stahl, M.</creator><creator>Kullmann, F.</creator><creator>Hebart, H.</creator><creator>Siveke, J.T.</creator><creator>Egger, M.</creator><creator>Homann, N.</creator><creator>Probst, S.</creator><creator>Al-Batran, S-E.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201709</creationdate><title>A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)</title><author>Pauligk, C. ; Lorenzen, S. ; Goetze, T. ; Riera Knorrenschild, J. ; Hegewisch Becker, S. ; Seraphin, J. ; Thuss-Patience, P. ; Kopp, H-G. ; Dechow, T. ; Vogel, A. ; Luley, K. ; Pink, D. ; Stahl, M. ; Kullmann, F. ; Hebart, H. ; Siveke, J.T. ; Egger, M. ; Homann, N. ; Probst, S. ; Al-Batran, S-E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1854-28b46211d8eb6f9d0e218b5f4de548be1ddfdd7dc6dcb985522f168ba79d72f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pauligk, C.</creatorcontrib><creatorcontrib>Lorenzen, S.</creatorcontrib><creatorcontrib>Goetze, T.</creatorcontrib><creatorcontrib>Riera Knorrenschild, J.</creatorcontrib><creatorcontrib>Hegewisch Becker, S.</creatorcontrib><creatorcontrib>Seraphin, J.</creatorcontrib><creatorcontrib>Thuss-Patience, P.</creatorcontrib><creatorcontrib>Kopp, H-G.</creatorcontrib><creatorcontrib>Dechow, T.</creatorcontrib><creatorcontrib>Vogel, A.</creatorcontrib><creatorcontrib>Luley, K.</creatorcontrib><creatorcontrib>Pink, D.</creatorcontrib><creatorcontrib>Stahl, M.</creatorcontrib><creatorcontrib>Kullmann, F.</creatorcontrib><creatorcontrib>Hebart, H.</creatorcontrib><creatorcontrib>Siveke, J.T.</creatorcontrib><creatorcontrib>Egger, M.</creatorcontrib><creatorcontrib>Homann, N.</creatorcontrib><creatorcontrib>Probst, S.</creatorcontrib><creatorcontrib>Al-Batran, S-E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pauligk, C.</au><au>Lorenzen, S.</au><au>Goetze, T.</au><au>Riera Knorrenschild, J.</au><au>Hegewisch Becker, S.</au><au>Seraphin, J.</au><au>Thuss-Patience, P.</au><au>Kopp, H-G.</au><au>Dechow, T.</au><au>Vogel, A.</au><au>Luley, K.</au><au>Pink, D.</au><au>Stahl, M.</au><au>Kullmann, F.</au><au>Hebart, H.</au><au>Siveke, J.T.</au><au>Egger, M.</au><au>Homann, N.</au><au>Probst, S.</au><au>Al-Batran, S-E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)</atitle><jtitle>Annals of oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>28</volume><spage>v228</spage><epage>v228</epage><pages>v228-v228</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdx369.054</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2017-09, Vol.28, p.v228-v228 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdx369_054 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T03%3A34%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20randomized,%20double-blind,%20multi-center%20phase%20III%20study%20evaluating%20paclitaxel%20with%20and%20without%20RAD001%20in%20patients%20with%20gastric%20or%20esophagogastric%20junction%20carcinoma%20who%20have%20progressed%20after%20therapy%20with%20a%20fluoropyrimidine/platinum-containing%20regimen%20(RADPAC)&rft.jtitle=Annals%20of%20oncology&rft.au=Pauligk,%20C.&rft.date=2017-09&rft.volume=28&rft.spage=v228&rft.epage=v228&rft.pages=v228-v228&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx369.054&rft_dat=%3Celsevier_cross%3ES0923753420379448%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753420379448&rfr_iscdi=true |